Investor Highlights

Current:

  • Investor Presentation - view here
  • Quarterly Shareholder Update - view here
  • Investment Summary - view here

Pharmaxis Drug Discoveries to be Studied by Respected Scientific Collaborators following Government Grants of $1.4m to Advance Cancer and Skin Disease Treatments

  • Associate Professor Thomas Cox from the Garvan Institute of Medical Research has been awarded an $827,500 NHMRC Development Grant to lead a multidisciplinary team investigating PXS-5505 as a promising new treatment approach for pancreatic cancer.
  • Professor Fiona Wood and Associate Professor Mark Fear of the University of Western Australia have been awarded a $590,200 NHMRC Drug Development Grant to work on a novel small molecule from the Pharmaxis pre-clinical pipeline for tissue repair and inflammatory skin disease.
Read full media release - pdf

Oversubscribed Pharmaxis Share Purchase Plan Raises $2.6million

  • Pharmaxis Share Purchase Plan oversubscribed
  • Increased from targeted $2.0 million to $2.6 million
  • Total of $9.8 million raised including placement and SPP
Read full media release - pdf

Pharmaxis Announces A$7.2m Placement and A$2.0m Share Purchase Plan

Highlights: 

  • A$7.2m being raised in an oversubscribed placement to institutional and sophisticated investors
  • Strong support from existing major shareholders together with new institutional shareholders joining the register
  • Strong pro-forma cash balance post raising  
  • Strengthened balance sheet to support next phase of clinical trials in bone cancer, liver cancer and wound and burns scarring  
  • Issue price of A$0.105 represents a 12.0% discount to the 5-day VWAP of $0.119
  • Share purchase plan to raise approximately $2.0 million to eligible shareholders
Read full media release - pdf

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

  • IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients
  • University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 2022
Read full media release - pdf

Pharmaxis Quarterly Shareholder Update and Investor Presentation

Watch a recording of the Pharmaxis Ltd September Quarterly Shareholder Update by the chief executive officer Mr Gary Phillips on Thursday 28 October 2021.

Watch recording here.